Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning and welcome, everyone, to the presentation of Apotea's third quarter report. We will, as usual, start with the presentation of the quarterly figures. After the presentation is done, we will move on to a Q&A with spoken questions. Today's presenters are as usual. Pär Svärdson, our CEO and co-founder. Johan Mårild, our CFO, and myself. Sarah Ahnström. Our CEO and deputy CEO. So let's begin with some highlights from the quarter.
We have had a good quarter with improved growth and profitability. So I am pleased to present the figures.
Yes. We had net revenue of 1,990 million SEK in Q3, close to 2 billion SEK. And we increased growth to 12.5% and adjusted EBIT margin to 5.4%.
And some updates from the quarter. Our focus has remained on growth. We have continued to launch and execute on several growth initiatives. We have also had an accelerated growth during the quarter that was driven by our prescribed medicine. And we have worked a lot with strengthening our customer offering, both in general, but also in our Rx in particular. And we can see that that has had an effect. We have also been working on how we present the products on our site. We have also broadened the assortment of our products available for the customers. And we have also made changes to the delivery experience. We are also glad to see that we have expanded the area of delivery to an additional 1 million people in Sweden, which adds up to 3.7 million people who can receive our orders the same day.
And we have continued to scale up in Norway. We had a soft launch in Norway this spring. With approximately 1 to 2 orders every day for quite a while. But it was very important to see that it was a good experience for all customers. And now after the summer, we have started to scale up and we can see really good figures in Norway. And I see a big potential in Norway. And I think over time, it will really help us grow. And we have also been recognized as the strongest online pharmacy brand for, I think, 9 or 10 years in a row. So we are very happy about that. But we will absolutely also continue to work much harder to receive that nomination for the next year as well.
And the R12 net revenue continues to increase. We have now surpassed 7.8 billion in net revenue. R12 adjusted EBIT margin for the same period was 4.3%, slightly up from 4.2% in Q2. Let's look closer at the numbers then. The growth in the quarter was 12.5%. Growth in this quarter was driven by strong growth of close to 19%. As we mentioned, it was supported by an improved offering in this area. And then to the right, you can see our gross margin development and gross margin was stable in the quarter. And then if you look year to date, it's even more stable. It was 27.5% year to date, which was very much in line with last year. We significantly improved our adjusted EBITDA in the quarter, and the improved profitability was the result of: You have a stable gross margin and continued good cost control and improved efficiency in our logistics, which was in turn supported by the successful launch and scale-up of the Varberg fulfilment centre. We launched the Varberg fulfilment centre a little bit more than a year ago, and the improved efficiency is also evident when looking on the right-hand side of this slide, where you can see the external expenses. And if you combine that with the cost of our personnel, it goes down year-over-year. Depreciation, however, increases as expected. And as a result of the Varberg fulfilment centre launch last year. Year-to-date. Year to date, we have a growth of 11.3%, and we have a slight increase in profitability even year to date, despite the higher depreciation as a result of Varberg. As mentioned. Our operating cash flow in the quarter was lower and impacted by changes in net working capital, which in turn is a result of the timing of purchases over a longer period. If you look at the last year or so, it was impacted by the build-up of inventory, and in the quarter, it is more a result of timing. NWC varies from quarter to quarter. Underlying, we have a strong operating cash flow and good cash conversion. We continue to have limited investments year-to-date and in Q3. Following the completion of the new Varberg fulfilment centre, we are focused on optimizing our operations and scaling up the operations in Varberg.
And if we look into the coming year for investments, I think we have been very focused on getting our Varberg fulfilment centre up and running. And hence, that has been the main focus. If we go ahead now, we have a very stable production environment, and we think that it is time to start evaluating coming investments in automation for the Varberg fulfilment centre and we have the capacity that we need currently. But we also know that it takes time to get automation in place and also takes time to get automation up and running. However, we have communicated the normal CapEx of 50 to 75 million Swedish crowns a year, and we do not expect any deviation from that during the coming year.
Inventory amounted to 840 million at the end of September, which was slightly down compared to Q2 and fairly stable compared to September last year. The inventory turnover metric came down somewhat compared to last year. And that is a result of how you calculate that metric where you have average inventory, which increased due to the build-up of inventory last year. Next slide. Yes, we continue to have a solid return on capital employed of 27 to 28%. And the decline compared to last year is related to the asset build-up related to the Varberg fulfilment centre. On the right-hand side, you see our balance sheet, which remains strong, with a net cash position of 111 million kronor at the end of September. And that is despite this build-up of inventory and the dividend paid out this spring.
Yeah. We started operations in the Varberg fulfilment centre about one year ago, as we have mentioned several times, and it was the biggest project in Apotea's history. I mean, if you look back now, one year later, it was a very successful project, I think, on time and on budget. It has really been good for Apotea. I mean, we started Q3 2025 by scaling up from zero and building stock. And after that, we scaled up.
Last year was also the first Black Week during Q4 with the two logistic centers. So we were super happy to have the additional capacity and automation during those peak sales days. However, we also gained a lot of experience regarding the additional complexity of purchasing and sending out campaign orders from two warehouses. We have since then, in the following quarters, really improved our way of working, in particular in purchasing.
And if we look at the first quarter this year, we scaled up, we added more shifts and worked more hours and also improved the capacity and sold a lot of orders. So we started to work very well.
During the second quarter of this year, we also launched Apotea.no in Norway. So we started sending our customer orders to our Norwegian customers from Varberg. And I think that has been a really good way for us to use the spare capacity in Varberg in an efficient way.
And now we have like 40% of all orders in Varberg, even more for these large and extra-large packages. And that is very important for us because they are fully automated in the Varberg fulfilment centre, whereas the others are quite manual. So it is very good for our costs. And if we look going forward, I think it works well now. But one year, two years, three years from now, it will work much better because it's still a journey. So there are a lot of things we can do much better, but it is a good investment so far. And if we focus a little bit ahead, we want to build the pharmacy for tomorrow. I have said that before and I will probably say it more times. What we mean by that is that we want to make continuous improvements every day. Make it a little bit better for our customers, a little bit better efficiency, and better overall performance. We continue to do that every day. And I think we have a good pace of it. And now we focus a lot on growth, as we have said. We have hundreds of projects related to growth. And that will continue to be our focus.
Exactly. And I think one part of this focus is, of course, also to continue to work on the customer offering and making improvements constantly within that. I think what has been evident during this quarter is the additional speed in getting these initiatives executed and implemented. I could say, especially within the tech initiatives, AI has really helped us to speed up the process of having tech initiatives implemented, and that has been something that I think will have a great impact also going forward and will accelerate the change in our customer offering. We will also continue to work, of course, with optimizing the logistics operations, as I mentioned. We will evaluate additional investments in automation in the Varberg fulfilment centre. And we are also very happy to see that a larger part of the packages are being shipped from the facility. But going ahead, we will also start to optimize the stock levels in both warehouses, which will, of course, have a positive impact. That was the end of the presentation. And we will now open up for Q&A.
Victoria. Yes. Can you.
Hear me? Can you hear me?
Yeah. Sorry.
Okay, perfect.
Thank you.
Let's go ahead.
Okay. Uh, good morning, sir. Are you well? Uh, yeah. Thanks. Good morning. Okay, so now I am the first person to ask a question, but I was third in line. I was third in line. But sometimes you're lucky. Exactly. Uh, yeah. Yeah. Yes. Excellent. Uh, yeah. So, thanks for taking my questions. Good report here this morning. I have a couple of questions. I will start with growth in traded goods. That slowed a bit to 8% year-on-year. It was down from the 10% which was delivered in both Q1 and Q2. So my question is, shouldn't it have benefited from a better consumer or external focus? A big uptick in SKUs, cross-selling from Rx, which grew nicely. So, what is behind the slower growth in other products that we have seen versus what we observed in the first half?
I think it goes up and down a little bit due to the number of days in the quarter, how many Mondays there are, and so on. So I think you need to look at a slightly longer series of quarters before you can say anything. So I am not worried about it. I mean, in another quarter, you will probably ask the same about Rx or something. But over time we will absolutely increase it.
Okay. Thanks. Next question. Looking at your EBIT margin. So this was another strong margin quarter. And this was despite the high-margin service revenue in absolute numbers being well below both Q1 and Q2, but also higher Rx sales, which some out there believe is negative for margins. You have again proven this wrong. So this was the third quarter in a row above 5% EBIT margin. And you've been above 5% in eight of your last ten quarters. At the same time, your short-term margin target from the IPO and before Varberg, that is at 3% to 5%. So my question is, why is this? Are you planning any very substantial cost increases for 2027? Because otherwise, it is a little bit hard to understand the seemingly low margin target that you have currently.
Yeah. But for us, it is very important that we can hold the corridor. So we are above it, and in the fourth quarter last year, we were not. So, I think we need at least one year before we change anything so we can see that we really can handle it.
And you should look at the EBIT margin over a full financial year. So you have all the quarters. You have historically had slightly, I mean, Q1, Q2, and Q3 are typically higher margins compared to Q4, where you have higher campaigns, for example.
Yeah. Yeah. For sure. Uh, okay. So we will stay tuned on that question, then I can do a final question and then I will let the other analysts that I jumped before ask some questions as well. So, my final question here on CapEx: you have guided for 50 to 70 million here in CapEx. You mentioned this in your presentation in the beginning as well. But for the first three quarters this year, it is only 8 million in total. So that would mean more than 40 in Q4. Is that correctly assumed?
Oh, sorry.
For the coming year. I think the guidance for CapEx is for the coming year. We don't see any deviations. So that is for 2027. And we have had a very strong focus on getting the Varberg fulfilment centre up and running. And this year, I think it is natural that you look into the production you have, get that up and running with stability, and learn from it. And then you evaluate the next step in investing in automation. I think we have reached that point, but it takes time. So we will start with the evaluation now. And I think the guidance is correct for 2027.
Okay, perfect. Thank you. I will get back to you later.
The next question comes from Johan. Fred from SEB. Please go ahead.
Good morning, everyone. Can you hear me now?
Yes.
We are very happy to be able to hear you as well.
Yeah. Me as well. Thank you for taking my question on the OTC growth. A strong 19% growth here in Q3. What is driving the strong growth in Rx specifically? Is it volume or is it the price mix tilt towards higher ticket? Regarding Rx articles, how sustainable is the growth rate going into 2027?
It is driven both by volume, but also by more expensive medicine-like products. Some of them are really expensive. But, in general, it is driven by a high demand in the market. And I think we absolutely can continue because we have a lot of projects in the pipeline to improve our sales. So.
Absolutely.
Got it, very clear. Thank you. And a follow-up on the question on gross margin here, the growth likely puts some pressure on the gross margin in percentage terms. But can you help us understand the decline in gross margin year on year, how much was driven by channel mix versus pricing or promotional activity.
Yeah. I mean.
Overall, Rx, as we have said before, has a lower gross margin than OTC, so that has, of course, an impact on the gross margin. It is more or less fairly stable as I pointed out, and as we see it, it varies somewhat between the quarters.
Yeah. But we have the opposite with sales of marketing contributions, private labels, and we can do better in purchasing and so on. So, I mean, we have one factor that decreased the gross margin and one that increased it. So we try to keep it stable.
Yeah. Yeah. But so in Q3 here, it was mostly mix from higher Rx sales rather than sort of price investments.
Yeah. I mean, we raise and lower prices every day, but in general, we say that we want to have a really stable gross margin and we will continue to have that.
Understood. Got it. And a question on Varberg, which is now handling around 40% of our sales; given the different types of orders handled at Varberg and Morgongåva, how should we think about the 40% split? Is this where you want to be long term, or should we expect the Varberg share to increase further as the ramp-up progresses?
I think in the short run, we will probably ramp it up a little bit more. But of course, as we grow, we have a certain capacity in our Varberg fulfilment centre. So if we continue to grow, it will go down again. So I think it's not a fixed level and it shall not be a fixed level either. So I think it will go up and down a little bit, but the important thing is to optimize. So we get a really good cost and efficiency in the total organization.
Got it. And one final question before I jump back in the queue again. Regarding Norway, you have been gradually scaling up the business throughout the year. What have you learned so far in terms of customer demand and also the competitive environment here? And what do you need to see before stepping up your investments in marketing and accelerating the rollout in Norway, or should we interpret your comments in Q3 as such? At this stage now.
I think we started, and now we are ramping up, and we see a really good response from the market. So I think in the coming year that we will have a contribution from Norway. Absolutely. And I see huge potential. I think we need to come back with exact figures on what we have and what we believe. But we absolutely have a strong belief.
I think we can also say that we're constantly improving the service to the Norwegian market. I think we also want to have a very strong offering when we scale up our marketing activities to a wider level. Each day, the offering in Norway becomes better. So we are trying to get to a very high level, of course.
But sorry, just a final follow-up on that topic. Building on Victor's question here earlier, is this the investment in Norway? Could that be something that you account for in terms of your margin target, and can we expect a heavier investment period in marketing and positioning in Norway that could essentially keep you in the 3 to 5% margin range in the coming quarters?
Generally, you can say that there are quite high price levels in Norway.
So Norway has a very efficient setup, of course, since we are distributing from the fully automated Varberg fulfilment centre. And as I said, it is also worth noting the price levels in Norway. I just want to reiterate that it is a very interesting market. It is a very promising launch. And at the same time, we are also very humbled that we are at the beginning of this ramp up. What matters is growth in millions of kronor rather than in percentage? So, it is going well.
Thank you. I will let Benjamin ask a few more questions. Thank you for taking the time.
Thank you.
Thank you.
The next question comes from Benjamin Wahlstedt from ABG. Please go ahead.
Hello.
A couple of questions from me as well. First of all, your headcount is down by approximately 45 FTEs year-on-year. Are these implicitly replaced by automation or what has happened here?
Of course, we try to improve all the time, but it also depends a little bit on how many consultants you have and how you calculate that. But of course, we try to improve our efficiency all the time. Mhm.
Perfect. I was wondering as well if you could break down the external opex ratio saving for us a bit more specifically, perhaps if you could comment on the marketing ratio and whether that changed materially.
We have an overall fairly stable marketing ratio in relation to sales. And then we don't break that out in terms of numbers, but it is more or less stable from quarter to quarter, year to date, and compared to last year. It goes down a little bit year-over-year. I mean, we try to.
But in percentage, it goes down. But in millions of Swedish kronor, it goes up. So we try to increase it a little bit every year. But as a percentage of the revenues, it goes a little bit down. Yeah.
Yeah. That is great.
All right. Maybe a final question from my end as well. And we are back to talking about the 3% to 5% margin target. On rough calculations, you could report a one percentage point lower margin in Q4 than Q3 and still hit the 5% margin for the full year. Of course, you highlight higher campaign pressure in Q4 as the reason for your caution. Which leads me to the question, how do you think we should think about the Q4 2025 comparable? Do you think it's a reasonable benchmark for typical Q4 gross margins, or was it sort of a one-off soft gross margin outcome back then?
Yeah, I can start and you can fill in, but 2025 was not a good year for us during Q4 because we had some problems. But if you look at 2024, 2023, and so on, we have had a little bit lower. I mean, Q4 is a weak quarter. But it was extra weak last year. So I think we shall aim and try to have a normal Q4 this year.
I think we had a significantly lower EBIT margin in Q4 last year compared to previous Q4 periods. So I don't think that's a representative benchmark. Um, absolutely.
And I guess that is sort of my point here as well; of course, campaign pressure is one thing, but driving these campaigns also provides scale on your fixed cost base. So why is it that you implicitly guide for a significant margin downturn into Q4?
We don't have a guidance for a specific Adjusted EBIT margin in Q4. And what we have tried to say with the financial targets is that we want to deliver for a full financial year, we want to capture performance across all quarters and all seasonalities. And then it becomes a question for after that. So kind of deliver first rather than that. Yeah. Deliver first.
To deliver.
Yeah. That is always best, isn't it? Thank you very much. That is all I have for now.
Thank you. Thank you.
The next question comes from Victor Hanson from Carnegie. Please go ahead.
Welcome back, Victor.
Hello. Yes. Thank you, thank you. A couple of follow-up questions. Firstly, regarding private label sales. I believe it was last quarter. You said it was above 100 million.
It's that we don't break that out. The private label and own products are not presented, but we continue to have strong growth. The number of SKUs in products is fairly stable. It is about 400 products.
I think we will probably continue to be around 400 because we now have a good portfolio of private label. And now we will rather improve them than add a lot more products.
Perfect. And then regarding Norway. Could you remind us how much of your sales currently comes from Norway?
We haven't split out Norway. When it comes to whether we will split that out on a quarterly basis. No, it is not.
But Norway, I mean, apotea.no and our pharmacy business in Norway. Apotea is growing nicely. Yes. And we will continue to grow.
We will continue to grow. Yeah. Great. At the time of the Norway launch, I believe it was about 2% of your sales. So maybe a little bit more now. Is that fine?
Fine?
I mean, Norway as a whole is growing faster than Sweden. So yes, it will increase over time as a percentage of sales.
I think during next year we can probably come back with better figures for you when it is more significant.
Yeah. It needs to be a bit more relevant as a whole before that.
Perfect. Another follow-up on Norway. Some previous comments that you made a couple quarters ago, or maybe it was even longer. You said that Norway was slightly below breakeven, but that was for Apotea, not for Apotea.no. I know that of course it is fulfilled from the Varberg fulfilment centre. So, now should Norway as a whole be profitable, correct?
Yeah. And the point of Norway, of course, is that we want to be. We want to grow. We want to do that. We want to be profitable there in a long-term and sustainable way. But during this ramp-up phase in Norway, the overall message is to be break-even or slightly positive rather than maximizing at the adjusted EBIT level. So that makes sense.
The setup for Apotea.no is very good because we can use spare capacity in the Varberg fulfilment centre to send products to Norway. And so the cost profile for that is very good.
Yeah, great. And it's roughly four hours by truck to Oslo. So it is relatively close. Yeah. Great. Okay, a final question then, another question on the market. So you have a strong margin. You could afford more marketing. Why aren't you doing it? Are your returns not good enough for more marketing to be worth it? I know you don't do much performance marketing. It's mostly higher in the funnel, building the brand. But aren't you considering doing more marketing to accelerate growth and fill your warehouses even more?
We look at different options.
Once you get the customers to try Apotea, they seem to be quite sticky as well. Just wanted to add that.
Yeah. And we try to find profitable marketing, just as we do with our investments. And if we find something that we think is good for us, we do it. So it's not that we're holding back, but we also need to find profitable marketing that we think is good for us.
Okay, perfect. Yeah. That's all for me. Thank you very much.
Thank you.
The next question comes from Johan Fred from CIB. Please go ahead.
Yes. Thank you for taking the follow-up questions from my side. So on the working capital in the presentation, you stated that this was related to timing, which of course makes sense, but just to follow up here, has there been any changes to your supplier terms or is there any trade-off between payment terms and purchasing price, for example, i.e. Could some of the working capital movement also be reflected in the margins?
No, I mean we have stable terms if you talk about accounts payable or debt to suppliers, etc. I mean, we have stable terms with them. Stable terms. So if that was your question.
We are improving them over time.
Yes. So, there is no trade-off between the shorter payment times and better or more discounts from suppliers then.
No, I mean.
No, not really.
No. And then we have a lot of suppliers, which is part of the commercial agreements for each individual supplier. This is part of that discussion, of course, but by and large, it is stable. And over time we try to be better.
Got it very clear. And the final one, just to follow up on Q4 last year and going into Black Week, it was obviously quite a challenging period for you from a margin perspective; what have you done differently this year to address those issues with inventory allocation between the warehouse and the campaign purchasing, etc. . And how confident are you that you can avoid a similar margin impact in Q4?
I mean, we have done so much, but one example is that the production is much more stable. We have learned a lot. We have different campaigns, and we have worked much more closely with our suppliers. And all these delivery chains have been so much better this year. And I really hope that we can avoid problems in the future. I mean, we cannot guarantee it, but I am quite certain that we can, so a lot has changed, so I do not think we shall.
Yes, absolutely.
I am not worried about it.
No, exactly. But I think, as I mentioned before, we try not to make the same mistake twice, but then again, you need to have respect for that. So we will try to avoid the mistakes that were made last year. Then there are, of course, other challenges all the time. But we try to be constantly improving, and we are in much better shape overall than last year.
Good. Confident. And in terms of overall market campaign activity, are you expecting a similar level of promotional intensity as last year?
Yes, I think in the market in general, it is a trend that is becoming more prevalent, and we will probably be at a similar level to last year.
Cool. Got it. Those were all my questions. Thank you so much once again for taking the time.
Thank you.
Thank you very much. And thank you for listening to the presentation. And thank you for your patience regarding the technical issues that we had, and we wish you all a pleasant day. Thank you for listening.
Thank you.



















